BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liu A, Le A, Zhang J, Wong C, Wong C, Henry L, Nguyen MH. Increasing co-morbidities in chronic hepatitis B patients: experience in primary care and referral practices during 2000-2015. Clin Transl Gastroenterol 2018;9:141. [PMID: 29540676 DOI: 10.1038/s41424-018-0007-6] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
Number Citing Articles
1 van der Spek DPC, Katwaroe WK, van Kleef LA, Brakenhoff S, de Man RA, de Knegt RJ, van der Meer AJ, Sonneveld MJ. Time-trends in disease characteristics and comorbidities in patients with chronic hepatitis B in the period 1980-2020. Eur J Intern Med 2023;107:86-92. [PMID: 36396524 DOI: 10.1016/j.ejim.2022.11.012] [Reference Citation Analysis]
2 Kang CK, Brennan PN, Dillon JF. How to Effectively Monitor Aging Patients with Chronic Hepatitis B: A Review. CIA 2022;Volume 17:1811-1820. [DOI: 10.2147/cia.s366255] [Reference Citation Analysis]
3 Martin P, Nguyen MH, Dieterich DT, Lau DT, Janssen HLA, Peters MG, Jacobson IM. Treatment Algorithm for Managing Chronic Hepatitis B Virus Infection in the United States: 2021 Update. Clin Gastroenterol Hepatol 2022;20:1766-75. [PMID: 34329775 DOI: 10.1016/j.cgh.2021.07.036] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
4 Chen J, Hubbard A, Bagley L, Shiau R, Wong RJ, Chitnis AS. Prevalence of Latent Tuberculosis Infection Among Persons with Chronic Hepatitis B Virus Infection: A Systematic Review and Meta-Analysis. Dig Dis Sci 2022;67:2646-54. [PMID: 34056681 DOI: 10.1007/s10620-021-07056-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Jo AJ, Choi WM, Kim HJ, Choi SH, Han S, Ko MJ, Lim YS. A risk scoring system to predict clinical events in chronic hepatitis B virus infection: A nationwide cohort study. J Viral Hepat 2022;29:115-23. [PMID: 34762757 DOI: 10.1111/jvh.13631] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Liu X, Qiu W, Liang Y, Zhang W, Qiu Q, Bai X, Dai G, Ma H, Hu H, Zhao W, Hu G. Effect of a Community-Based Hepatitis B Virus Infection Detection Combined with Vaccination Program in China. Vaccines (Basel) 2021;10:19. [PMID: 35062680 DOI: 10.3390/vaccines10010019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Duan Y, Chen Z, Li H, Shen W, Zeng Y, Peng M, Hu P. Potential Molecular Targets of Tenofovir Disoproxil Fumarate for Alleviating Chronic Liver Diseases via a Non-Antiviral Effect in a Normal Mouse Model. Front Mol Biosci 2021;8:763150. [PMID: 34869594 DOI: 10.3389/fmolb.2021.763150] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 De Pasquale C, Campana S, Barberi C, Sidoti Migliore G, Oliveri D, Lanza M, Musolino C, Raimondo G, Ferrone S, Pollicino T, Ferlazzo G. Human Hepatitis B Virus Negatively Impacts the Protective Immune Crosstalk Between Natural Killer and Dendritic Cells. Hepatology 2021;74:550-65. [PMID: 33482027 DOI: 10.1002/hep.31725] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
9 Fabrizi F, Cerutti R, Alfieri CM, Ridruejo E. An Update on Hepatocellular Carcinoma in Chronic Kidney Disease. Cancers (Basel) 2021;13:3617. [PMID: 34298832 DOI: 10.3390/cancers13143617] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
10 Chitnis AS, Cheung R, Gish RG, Wong RJ. Epidemiology and Prevention of Tuberculosis and Chronic Hepatitis B Virus Infection in the United States. J Immigr Minor Health 2021. [PMID: 34160726 DOI: 10.1007/s10903-021-01231-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Hou J, Chen W, Han Y, Wang L, Lee IH, Hsu LI, Xie D, Yin X, Hou F, Yang Y. Shifting demographics and comorbidity burden in adult Chinese urban patients with chronic hepatitis B, 2013 and 2016. J Comp Eff Res 2021;10:647-57. [PMID: 33970683 DOI: 10.2217/cer-2020-0080] [Reference Citation Analysis]
12 Zhang Y, Xu W, Zhu X, Li X, Li J, Shu X, Lai J, Xie J, Xie C, Peng L. The 48-week safety and therapeutic effects of tenofovir alafenamide in hbv-related acute-on-chronic liver failure: A prospective cohort study. J Viral Hepat 2021;28:592-600. [PMID: 33423348 DOI: 10.1111/jvh.13468] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
13 Gu J, Yu G, Zhang X, Zhang S, Cai H, Ye C, Yang Y, Li D, Tong Z, Shen H, Chen H, Ding F, Lai X, Liu J, Xu M, Wu W. Cross-sectional retrospective analysis of clinical characteristics of chronic hepatitis B patients with oral antiviral treatment in eastern China. Virol J 2021;18:19. [PMID: 33441170 DOI: 10.1186/s12985-021-01491-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Liang L, Huang DS, Yang T. Editorial: comorbidities in patients with chronic hepatitis B. Aliment Pharmacol Ther 2020;52:891-2. [PMID: 32852837 DOI: 10.1111/apt.15938] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
15 Zhou K, Dodge JL, Grab J, Poltavskiy E, Terrault NA. Mortality in adults with chronic hepatitis B infection in the United States: a population-based study. Aliment Pharmacol Ther 2020;52:382-9. [PMID: 32432816 DOI: 10.1111/apt.15803] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
16 Oh H, Jun DW, Lee IH, Ahn HJ, Kim BO, Jung S, Nguyen MH. Increasing comorbidities in a South Korea insured population-based cohort of patients with chronic hepatitis B. Aliment Pharmacol Ther 2020;52:371-81. [PMID: 32542860 DOI: 10.1111/apt.15867] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 5.3] [Reference Citation Analysis]
17 Nguyen MH. Reply. Hepatology 2020;71:1519. [PMID: 30762889 DOI: 10.1002/hep.30560] [Reference Citation Analysis]
18 Nguyen MH, Wong G, Gane E, Kao JH, Dusheiko G. Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy. Clin Microbiol Rev. 2020;33. [PMID: 32102898 DOI: 10.1128/cmr.00046-19] [Cited by in Crossref: 100] [Cited by in F6Publishing: 106] [Article Influence: 33.3] [Reference Citation Analysis]
19 Choi HSJ, Brouwer WP, Zanjir WMR, de Man RA, Feld JJ, Hansen BE, Janssen HLA, Patel K. Nonalcoholic Steatohepatitis Is Associated With Liver-Related Outcomes and All-Cause Mortality in Chronic Hepatitis B. Hepatology 2020;71:539-48. [PMID: 31309589 DOI: 10.1002/hep.30857] [Cited by in Crossref: 73] [Cited by in F6Publishing: 60] [Article Influence: 24.3] [Reference Citation Analysis]
20 Price JC, Bhattacharya D. Editorial: HBV-the promise of a new era in therapeutics. Aliment Pharmacol Ther 2020;51:479-80. [PMID: 31990396 DOI: 10.1111/apt.15628] [Reference Citation Analysis]
21 Smolders EJ, Burger DM, Feld JJ, Kiser JJ. Review article: clinical pharmacology of current and investigational hepatitis B virus therapies. Aliment Pharmacol Ther 2020;51:231-43. [PMID: 31840863 DOI: 10.1111/apt.15581] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 8.7] [Reference Citation Analysis]
22 Wei MT, Nguyen MH, Cheung R. Epidemiology, Diagnosis, and Management of Bone Disease in Patients with Chronic HBV Infection. Curr Hepatology Rep 2019;18:322-330. [DOI: 10.1007/s11901-019-00481-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
23 Strasser SI, Thompson AJ, Roberts SK, George J; Clinical Cases in Hepatitis 2018 Steering Committee. Clinical Cases in Hepatitis: Towards improving liver disease management in Australia. J Gastroenterol Hepatol 2019;34 Suppl 1:5-15. [PMID: 31282011 DOI: 10.1111/jgh.14720] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
24 Nguyen MH, Lim JK, Burak Ozbay A, Fraysse J, Liou I, Meyer N, Dusheiko G, Gordon SC. Advancing Age and Comorbidity in a US Insured Population-Based Cohort of Patients With Chronic Hepatitis B. Hepatology 2019;69:959-73. [PMID: 30175482 DOI: 10.1002/hep.30246] [Cited by in Crossref: 46] [Cited by in F6Publishing: 29] [Article Influence: 11.5] [Reference Citation Analysis]
25 Le TV, Vu TTM, Mai HT, Nguyen LH, Truong NT, Hoang CL, Nguyen SH, Nguyen CT, Nguyen BC, Tran TH, Tran BX, Latkin CA, Ho CSH, Ho RCM. Social Determinants of Stigma and Discrimination in Vietnamese Patients with Chronic Hepatitis B. Int J Environ Res Public Health 2019;16:E398. [PMID: 30708943 DOI: 10.3390/ijerph16030398] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
26 Nguyen MH, Burak Ozbay A, Liou I, Meyer N, Gordon SC, Dusheiko G, Lim JK. Healthcare resource utilization and costs by disease severity in an insured national sample of US patients with chronic hepatitis B. J Hepatol 2019;70:24-32. [PMID: 30287341 DOI: 10.1016/j.jhep.2018.09.021] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]